학술논문

THE ADMINISTRATION OF DASATINIB AT HALF DOSE FOR TOXICITY DOES NOT COMMIT THE MOLECULAR RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA BUT DOES NOT SUBSTANTIOUSLY IMPROVE THE TOLERANCE